Alecensa®

Active substance

Alectinib

Holder

Roche

Status

Closed

Indication

First-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Public documents

Approbation

Information for the patient

Informed consent

Last update

03/09/2018